AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04067986 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
Study NCT00986804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT02114060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
Study NCT02114060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
Study NCT02114060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (25μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Study NCT01328665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Writing intervention for cognitive appraisal of stressor.
Study NCT01397643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-operative
Description: Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
Study NCT01397643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Operative
Description: For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
Study NCT00749021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg of intravitreal ranibizumab monthly for 12 months
Study NCT00749021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
Study NCT00749021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 2.0mg of intravitreal ranibizumab monthly for 12 months
Study NCT00749021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
Study NCT04810130 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Soccer Kicking
Description: Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
Study NCT04810130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading (Frontal)
Description: Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
Study NCT02114060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (50μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Study NCT02114060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (75μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Study NCT02114060 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline (NaCl)
Study NCT04414488 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracic paravertebral block (ThPVB)
Description: Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
Study NCT04810130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading (Oblique)
Description: Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
Study NCT01607307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral/enteral TJ-100 solution
Description: Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
Study NCT01300767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (AIR OPTIX® AQUA)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
Study NCT01300767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balafilcon A contact lens (PureVision® 2)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
Study NCT01300767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
Study NCT01300767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
Study NCT01690988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Description: Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Study NCT01607307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral/enteral placebo solution
Description: Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
Study NCT01690988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (placebo)
Description: Normal saline IV following induction of anesthesia or administration of sedative medications
Study NCT01690988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg)
Description: Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Study NCT05381389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride in-plane approach for the interscalene block
Description: 20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
Study NCT05381389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride out of-plane approach for the interscalene block
Description: 20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
Study NCT02887365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Study NCT02217683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
Study NCT02192619 — intervention group
Intervention type: OTHER
Intervention: observational
Study NCT02304419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally.
Study NCT04097080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTX-001
Description: Active drug group will receive 6 doses of NBTX-001 given three times a week.
Study NCT04097080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Placebo group will receive reconstituted air given three times a week.
Study NCT01608529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feel Breathe, restriction device ventilatory nasal
Description: The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
Study NCT01983449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection, USP
Description: Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
Study NCT02944734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
Study NCT02944734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 16mg
Description: Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
Study NCT02944734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Amlodipine 5mg Daily oral administration for 8 weeks
Study NCT02944734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Amlodipine 10mg Daily oral administration for 8 weeks
Study NCT02972281 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunological diagnosis tests
Description: (Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
Study NCT01188460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help manual for insomnia
Description: Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
Study NCT01188460 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep diary
Study NCT01188460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep diary
Study NCT04119388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted sports practices
Description: Adapted sports practices for 30 minutes twice a week
Study NCT03661255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC CARES
Description: PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
Study NCT02518542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic intervention A
Description: POEM: Per oral endoscopic myotomy
Study NCT02518542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic intervention B
Description: PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
Study NCT02518542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic intervention C
Description: Endoscopic balloon dilatation
Study NCT02518542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: Laparoscopic Heller myotomy
Study NCT00329784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut Consumption Group
Description: Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
Study NCT01916187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Study NCT01098032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard system
Description: The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate >300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
Study NCT01098032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic alone therapy
Description: Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
Study NCT02262013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Coaches
Description: Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
Study NCT02262013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Weight Loss
Description: Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
Study NCT03101449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finnish tube
Description: Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
Study NCT03101449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staw phonation
Description: Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
Study NCT00760890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol (ferrous sulfate)
Description: 7.5 mg/day in the form of 0.3 ml once each day
Study NCT00760890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified cereal
Description: 1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
Study NCT02252588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Oral Rinse
Study NCT02252588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine
Description: Oral Rinse
Study NCT02252588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Rinse
Study NCT02827877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA-Trastuzumab
Description: Given IV
Study NCT02252588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Rinse
Study NCT02827877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02827877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT02827877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT02827877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02827877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT03679650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
Study NCT03679650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/AML fusion cells
Description: An investigational agent that tries to help the immune system to recognize and fight against cancer cells
Study NCT02219672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triplitode
Description: Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir .
Study NCT02219672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir
Description: Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
Study NCT02714023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Intra-operative irrigation with normal saline
Study NCT02714023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Water
Description: Intra-operative irrigation with sterile water
Study NCT03723785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
Study NCT04024241 — intervention group
Intervention type: DEVICE
Intervention: Flow Cytometer
Description: high dose
Study NCT04024241 — intervention group
Intervention type: DRUG
Intervention: Mitoxantrone
Description: high dose
Study NCT04024241 — intervention group
Intervention type: DRUG
Intervention: Cytarabine
Description: high dose
Study NCT03756662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARGOS-SC suprachoroidal pressure sensor
Description: The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
Study NCT01297023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate
Description: 20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]
Study NCT01297023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin d
Description: 20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]
Study NCT01297023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate and vitamin d
Description: 20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]
Study NCT01297023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: All participants consume two weeks before intervention a bread without calcium an vitamin d.